Melanoma Research最新文献_第2页

MHC class II: a predictor of outcome in melanoma treated with immune checkpoint inhibitors. MHC II类：免疫检查点抑制剂治疗黑色素瘤的预后预测因子

IF 1.5 4区医学

Melanoma Research Pub Date : 2025-06-01 Epub Date: 2025-02-12 DOI: 10.1097/CMR.0000000000001022

Karim Amrane, Pierre Le Noac'h, Patrice Hemon, Ronan Abgral, Coline Le Meur, Olivier Pradier, Laurent Misery, Delphine Legoupil, Christian Berthou, Arnaud Uguen

{"title":"MHC class II: a predictor of outcome in melanoma treated with immune checkpoint inhibitors.","authors":"Karim Amrane, Pierre Le Noac'h, Patrice Hemon, Ronan Abgral, Coline Le Meur, Olivier Pradier, Laurent Misery, Delphine Legoupil, Christian Berthou, Arnaud Uguen","doi":"10.1097/CMR.0000000000001022","DOIUrl":"10.1097/CMR.0000000000001022","url":null,"abstract":"This study aimed to evaluate the predictive value of MHC class II (MHC-II) expression by melanoma cells in a large cohort of metastatic cutaneous melanoma patients treated with immune checkpoint inhibitors (ICIs). We conducted a single-center, retrospective study involving stage IV cutaneous melanoma patients who received ICI as first-line therapy. MHC-II expression in melanoma cells was quantified using dual-color anti-SOX10 and anti-MHC-II immunohistochemistry on tumor samples from 95 patients. The primary endpoint was event-free survival (EFS), with secondary endpoints including 1-year EFS, 1-year overall survival (OS), disease control rate (DCR), and the correlation between MHC-II expression and clinico-biological characteristics. The cohort had a median age of 67 years (range, 33-90), with a male-to-female ratio of 50 : 45. Thirty-three percent of patients received the ipilimumab-nivolumab combination. The median follow-up was 16.8 months. Disease progression occurred in 58 patients (61%), with a median time to progression of 4.8 months. Forty-six patients (48.4%) experienced an event within the first year, and 52 patients (54.7%) died during follow-up. MHC-II positivity was observed in ≥10% of melanoma cells in 6.3% of patients. MHC-II expression was significantly associated with 1-year EFS ( P = 0.037) and DCR ( P = 0.032), but not with EFS or 1-year OS. Age, phototype, and brain metastases were correlated with MHC-II expression status. Our findings suggest that MHC-II expression by melanoma cells may serve as a favorable predictive biomarker for survival in metastatic cutaneous melanoma patients treated with ICIs.","PeriodicalId":18550,"journal":{"name":"Melanoma Research","volume":" ","pages":"176-186"},"PeriodicalIF":1.5,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143409019","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Nivolumab-induced immune-mediated acute gastritis in a melanoma patient. 一名黑色素瘤患者因免疫介导的急性胃炎而服用 Nivolumab。

IF 1.5 4区医学

Melanoma Research Pub Date : 2025-06-01 Epub Date: 2025-03-21 DOI: 10.1097/CMR.0000000000001034

Faruk Tas, Emel Ahishali, Orhun Cig Taskin

引用次数: 0

Multiple primary melanomas in Udine, northeastern Italy: a focus on epidemiology and new risk factors. 意大利东北部乌迪内多发原发性黑色素瘤：流行病学和新危险因素的焦点

IF 1.5 4区医学

Melanoma Research Pub Date : 2025-06-01 Epub Date: 2025-02-27 DOI: 10.1097/CMR.0000000000001029

Alba Guglielmo, Alba De Benedittis, Cinzia Buligan, Enrico Zelin, Giuseppe Stinco

{"title":"Multiple primary melanomas in Udine, northeastern Italy: a focus on epidemiology and new risk factors.","authors":"Alba Guglielmo, Alba De Benedittis, Cinzia Buligan, Enrico Zelin, Giuseppe Stinco","doi":"10.1097/CMR.0000000000001029","DOIUrl":"10.1097/CMR.0000000000001029","url":null,"abstract":"Patients diagnosed with melanoma are at an elevated risk of developing subsequent primary melanomas. The aim of this study was to assess the prevalence and identify the risk factors associated with multiple primary melanomas (MPMs) in patients referred to the melanoma outpatient service of the Dermatology Unit at the University Hospital of Udine, Italy. We conducted a retrospective analysis on patients with MPMs. For each patient demographic, clinical, and histological data were collected. For each excised melanoma, we recorded Breslow thickness, histological subtype, and anatomical site. A total of 233 patients with melanoma were included in the study, comprising a subgroup of 51 (22%) patients diagnosed with MPM. The mean Breslow thickness for patients with a single melanoma was significantly higher than the Breslow thickness for the first melanoma in the MPM subgroup. Furthermore, a statistically significant decrease in Breslow thickness between the first and second melanomas was observed. In our cohort, patients with MPM had a significantly higher prevalence of nonmelanoma skin cancers (NMSCs) compared with those with a single melanoma. Our study indicates that the prevalence of MPM in the province of Udine is among the highest reported globally. Our finding aligns with the broader literature, which consistently reports lower thickness in second melanoma compared with first melanoma. Finally, the higher prevalence of NMSC in these patients suggests a potential link to chronic ultraviolet exposure.","PeriodicalId":18550,"journal":{"name":"Melanoma Research","volume":" ","pages":"208-212"},"PeriodicalIF":1.5,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143516140","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Diagnosis and management of concurrent metastatic melanoma and chronic myelomonocytic leukemia. 并发转移性黑色素瘤和慢性粒细胞白血病的诊断和治疗。

IF 1.5 4区医学

Melanoma Research Pub Date : 2025-06-01 Epub Date: 2025-02-04 DOI: 10.1097/CMR.0000000000001025

Kishan A Bhatt, Anna J Vaynrub, Jason Cham, Sunil G Iyer, Benjamin Izar

引用次数: 0

Nomograms versus artificial intelligence platforms: which one can better predict sentinel node positivity in melanoma patients? nomograph与人工智能平台：哪一个能更好地预测黑色素瘤患者前哨淋巴结阳性？

IF 1.5 4区医学

Melanoma Research Pub Date : 2025-05-27 DOI: 10.1097/CMR.0000000000001047

Eduardo Bertolli, Sara B Micheletti, Veridiana P de Camargo, Tiago V da Silva, Carlos E Bacchi, Antonio C Buzaid

{"title":"Nomograms versus artificial intelligence platforms: which one can better predict sentinel node positivity in melanoma patients?","authors":"Eduardo Bertolli, Sara B Micheletti, Veridiana P de Camargo, Tiago V da Silva, Carlos E Bacchi, Antonio C Buzaid","doi":"10.1097/CMR.0000000000001047","DOIUrl":"10.1097/CMR.0000000000001047","url":null,"abstract":"Nomograms are commonly used in oncology to assist clinicians in individualized decision-making processes, such as considering sentinel node biopsy (SNB) for melanoma patients. Concurrently, artificial intelligence (AI) is increasingly being utilized in medical predictions. This study aims to compare the predictive accuracy of nomograms and AI platforms for SNB positivity in a real-world cohort of melanoma patients. A retrospective analysis of melanoma patients who underwent SNB from 2020 to 2024 in a single institution was performed. Three open-access nomograms and three public AI platforms were employed to assess SNB positivity based on comprehensive clinical and pathological characteristics. Our cohort comprised 62 melanoma patients who have undergone SNB, of whom 12 (19.4%) were positive. There was no concordance among the three nomograms, nor among AI platforms ( P < 0.001). Only the Memorial Sloan Kettering Cancer Center (MSKCC) nomogram scored statistically different between positive and negative SNB ( P = 0.04), and ChatGPT was the only AI platform that was also statistically significant ( P = 0.02). Only ChatGPT score was statistically significant for SNB positivity after univariate logistic regression (odds ratio: 1.05; 95% confidence interval: 1.004-1.108; P = 0.03). A receiver operating characteristic curve based on ChatGPT predictions generated a model with an area under the curve (AUC) of 0.702. Integrating MSKCC predictions marginally improved the model's predictive performance, enhancing the AUC to 0.715. In conclusion, SNB positivity could be better performed by an AI platform in this cohort of patients. Enhancing AI platforms could provide better populations for nomogram validation, which would lead to better predictive models.","PeriodicalId":18550,"journal":{"name":"Melanoma Research","volume":" ","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144216325","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evaluation of surgical modalities for stage 0 to stage II acral lentiginous melanoma: a National Cancer Database study. 评估0期至II期肢端晶状体黑色素瘤的手术方式：一项国家癌症数据库研究。

IF 1.5 4区医学

Melanoma Research Pub Date : 2025-05-27 DOI: 10.1097/CMR.0000000000001046

Reagan F Blohowiak, Nicole W Welch, Bryce W Rigden, Rahul M Varman, Peter T Silberstein, Marco J DiBlasi

{"title":"Evaluation of surgical modalities for stage 0 to stage II acral lentiginous melanoma: a National Cancer Database study.","authors":"Reagan F Blohowiak, Nicole W Welch, Bryce W Rigden, Rahul M Varman, Peter T Silberstein, Marco J DiBlasi","doi":"10.1097/CMR.0000000000001046","DOIUrl":"https://doi.org/10.1097/CMR.0000000000001046","url":null,"abstract":"Wide local excision (WLE) is the standing surgical choice for acral lentiginous melanoma (ALM), yet research is scarce in evaluating other surgical options for ALM and its recurrence rates remain two to five times more likely than other melanoma subtypes. This study evaluates the overall survival outcomes associated with different surgical modalities in patients with stage 0-II ALM. This retrospective cohort study surveyed the National Cancer Database from 2004 to 2021 for International Classification of Diseases-10 codes specific for all skin structures with histologically confirmed ALM for stage 0-II patients. Using IBM SPSS, statistical analyses were conducted via variable frequency with crosstabulations and Chi-squared tests, Kaplan-Meier survival curves with log-rank pairwise comparisons, and Cox proportional hazards regression models. Data for 6737 patients showed significantly greater overall survival for biopsy followed by gross excision (BFGE) than WLE [median overall survival = 204.8 months (P < 0.001); hazard ratio = 0.77 (95% confidence interval, 0.68-0.87)]. Median overall survival for WLE was 181.6 months. Cross analysis of Breslow depth (BD) with surgical procedures revealed the majority (21.8%) of WLEs were completed for lesions with a BD of 0.1-5 mm followed by 16.8% for lesions greater than 3 cm (P < 0.001). Crossanalysis of surgical margins of the primary site with surgical procedures, showed no residual tumor in 92.1% of all BFGE patients, which is 3.7% and 3.3% less patients than major amputation and WLE. This study highlights significant differences across ALM surgery options, suggesting each modality has their own niche and BFGE should be investigated further.","PeriodicalId":18550,"journal":{"name":"Melanoma Research","volume":" ","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144216323","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Melanoma and pregnant women: a systematic review and meta-analysis. 黑色素瘤与孕妇：一项系统回顾和荟萃分析。

IF 1.5 4区医学

Melanoma Research Pub Date : 2025-05-27 DOI: 10.1097/CMR.0000000000001043

Michele Kreuz, Pedro Henrique de Souza Wagner, Larissa E Tanimoto, Vitor A da Rosa, Barbara Antonia D Talah, Francisco Cezar A de Moraes

{"title":"Melanoma and pregnant women: a systematic review and meta-analysis.","authors":"Michele Kreuz, Pedro Henrique de Souza Wagner, Larissa E Tanimoto, Vitor A da Rosa, Barbara Antonia D Talah, Francisco Cezar A de Moraes","doi":"10.1097/CMR.0000000000001043","DOIUrl":"https://doi.org/10.1097/CMR.0000000000001043","url":null,"abstract":"Pregnancy-associated melanoma is melanoma that can develop up to 1 year postpregnancy. There is no solid evidence on how pregnancy can affect melanoma survival, recurrence, or mortality. This systematic review and meta-analysis aims to analyze the overall survival (OS), recurrence, and mortality rate in pregnant women diagnosed with melanoma. A comprehensive search was performed on Medline, Embase, and Web of Science to identify studies comparing melanoma in pregnant versus nonpregnant women. Hazard ratios (HRs) and risk ratios (RRs) with 95% confidence intervals (CIs) were estimated using a random-effects model. Heterogeneity was evaluated using the I2 statistic, and significance was defined as P values less than 0.05. Statistical analyses were conducted using RStudio 4.4.1. Our meta-analysis included 15 studies, consisting of 29 095 patients; 2917 (10%) were pregnant women. In the OS outcome, statistically significant differences were observed, favoring pregnant women in comparison to nonpregnant women; both groups were diagnosed with melanoma (HR: 0.81, 95% CI: 0.69-0.95, P = 0.012, I2 = 85.4%). The OS at 5 years did not show statistically significant differences (OR: 1.08, 95% CI: 0.50-2.35, P = 0.83, I2 = 57.9%). Similarly, the outcomes of melanoma recurrence (RR: 1.19, 95% CI: 0.95-1.48, P = 0.12, I2 = 0%) and mortality (RR: 1.60, 95% CI: 0.82-3.13, P = 0.16, I2 = 73.5%) also showed no statistically significant differences between groups. According to this systematic review and meta-analysis, pregnant women diagnosed with melanoma have a higher OS rate than nonpregnant women.","PeriodicalId":18550,"journal":{"name":"Melanoma Research","volume":" ","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144216324","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Successful use of nivolumab and relatlimab as salvage therapy for metastatic uveal melanoma. 成功使用纳武单抗和relatlimab作为转移性葡萄膜黑色素瘤的挽救性治疗。

IF 1.5 4区医学

Melanoma Research Pub Date : 2025-05-27 DOI: 10.1097/CMR.0000000000001045

Ritwick S Mynam, Nandakumar Menon, Alexander Birbrair, Vincent T Ma

引用次数: 0

Impact of systemic imaging surveillance on survival from metastatic uveal melanoma. 系统性影像学监测对转移性葡萄膜黑色素瘤存活的影响。

IF 1.5 4区医学

Melanoma Research Pub Date : 2025-05-19 DOI: 10.1097/CMR.0000000000001042

Velvet Van Ryan, David Zahrieh, Carrie Strand, Robert A Churchill, Lauren A Dalvin, Arkadiusz Z Dudek

{"title":"Impact of systemic imaging surveillance on survival from metastatic uveal melanoma.","authors":"Velvet Van Ryan, David Zahrieh, Carrie Strand, Robert A Churchill, Lauren A Dalvin, Arkadiusz Z Dudek","doi":"10.1097/CMR.0000000000001042","DOIUrl":"https://doi.org/10.1097/CMR.0000000000001042","url":null,"abstract":"The National Comprehensive Cancer Network (NCCN) recommended surveillance imaging intervals for uveal melanoma (UM) based on the risk of distant metastasis. The objective of this research is to evaluate if patients, treated at our tertiary cancer center, who had scans consistent with these guidelines, had improved overall survival (OS). This was a single-center, retrospective study of UM patients, who developed metastatic disease. Patients were grouped into risk-of-metastasis cohorts (low, medium, and high-risk) based on the UM NCCN guidelines v1.2023. The frequency of scans was reported within annual intervals for 5 years within the low-risk cohort and for 10 years within the medium-risk cohort, and within 6-month intervals for the first 5 years and then annually in years 6-10 within the high-risk cohort. Conditional landmark analyses were used to evaluate the relationship between OS and consistency with guidelines. Scan frequency was evaluated against socioeconomic status. Of the 740 UM patients identified (1997-2020), 110 experienced metastasis and comprised our analysis population (20 low-risk; 67 medium-risk; and 23 high-risk). The median time to death (95% confidence interval) from diagnosis of metastasis was similar between the low, medium, and high-risk cohorts at 1.2 (1.0, 2.0), 2.0 (1.7, 2.6), and 1.6 (1.3, 2.3) years, respectively. For each cohort, the OS results were similar between those who followed guidelines vs. not at each annual landmark time. Living in disadvantaged areas did not impact imaging frequency (all P > 0.05). Imaging at intervals outlined by the NCCN guidelines v1.2023 did not impact OS for patients who developed metastatic UM.","PeriodicalId":18550,"journal":{"name":"Melanoma Research","volume":" ","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144094191","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Circulating tumor DNA predicts tumor progression and poor survival in patients with stage III melanoma. 循环肿瘤DNA预测III期黑色素瘤患者的肿瘤进展和不良生存率。

IF 1.5 4区医学

Melanoma Research Pub Date : 2025-05-19 DOI: 10.1097/CMR.0000000000001041

Rodolfo David Palacios-Diaz, Blanca de Unamuno-Bustos, Amara Carratalá-García, Gema Pérez-Simó, David Moreno-Ramírez, Lara Ferrándiz, Francisco Manuel Almazán-Fernández, Aram Boada, Leyre Loidi-Pascual, Sarai Palanca-Suela, Rafael Botella-Estrada

{"title":"Circulating tumor DNA predicts tumor progression and poor survival in patients with stage III melanoma.","authors":"Rodolfo David Palacios-Diaz, Blanca de Unamuno-Bustos, Amara Carratalá-García, Gema Pérez-Simó, David Moreno-Ramírez, Lara Ferrándiz, Francisco Manuel Almazán-Fernández, Aram Boada, Leyre Loidi-Pascual, Sarai Palanca-Suela, Rafael Botella-Estrada","doi":"10.1097/CMR.0000000000001041","DOIUrl":"https://doi.org/10.1097/CMR.0000000000001041","url":null,"abstract":"Data regarding circulating tumor DNA (ctDNA) in stage III melanoma are scarce. The main objective was to analyze the usefulness of ctDNA determination in predicting tumor progression in patients with stage III melanoma. A prospective multicenter study was designed based on patients with stage III cutaneous melanoma. We studied BRAF, NRAS, and TERT promoter mutations in primary or metastatic tumors. Blood samples were collected after detecting a positive lymph node by sentinel lymph node biopsy; preoperative in patients with lymph node metastasis; or before any treatment in patients with confirmed unresectable lymph node metastasis or in-transit metastasis; 4 weeks after lymph node surgery (postoperative); and every 3 or 6 months after the baseline sample. From each sample, we isolated cell-free DNA, and previously identified mutations were searched for to identify ctDNA. ctDNA was detected in 21 (21/48, 43.8%) patients. Recurrence at a distant site and recurrence in two or more locations were associated with ctDNA detection at the time of recurrence (P < 0.05). Plasma ctDNA detection at any time during follow-up was significantly associated with progression (P = 0.011), overall mortality (P < 0.001), and melanoma-specific death (P < 0.001). We did not find an association between detectable ctDNA before surgery and disease progression; however, patients with detectable postsurgical ctDNA exhibited a lower recurrence-free survival, overall survival, and melanoma-specific survival. Prospective longitudinal blood sampling for the identification of ctDNA provides information regarding recurrence and survival.","PeriodicalId":18550,"journal":{"name":"Melanoma Research","volume":" ","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144094184","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0